Table 1.
Participant characteristics.
| Country n = 43 | n | [%] | Continent n = 142 | n | [%] |
|---|---|---|---|---|---|
| Argentina | 4 | 2.8 | Europe | 79 | 55.6 |
| Australia | 3 | 2.1 | America | 31 | 21.7 |
| Austria | 3 | 2.1 | Asia | 13 | 9.1 |
| Belarus | 1 | 0.7 | Africa | 15 | 10.5 |
| Brazil | 6 | 4.2 | Oceania | 4 | 2.8 |
| Chile | 1 | 0.7 | European vs. non-European countries | n | [%] |
| Czech Republic | 2 | 1.4 | Non-European | 63 | 44.4 |
| Egypt | 2 | 1.4 | European | 79 | 55.6 |
| Finland | 2 | 1.4 | Medical specialty* | n | [%] |
| France | 3 | 2.1 | Infectious Diseases | 69 | 48.6 |
| Germany | 32 | 22.5 | Hematology | 68 | 47.9 |
| Hungary | 1 | 0.7 | Microbiology | 15 | 10.6 |
| India | 4 | 2.8 | Intensive Care | 8 | 5.6 |
| Indonesia | 1 | 0.7 | Oncology | 6 | 4.2 |
| Israel | 2 | 1.4 | Pediatrics | 4 | 2.8 |
| Italy | 11 | 7.7 | other | 8 | 5.6 |
| Lebanon | 2 | 1.4 | |||
| Malaysia | 3 | 2.1 | |||
| Mexico | 1 | 0.7 | |||
| Nepal | 1 | 0.7 | |||
| Netherlands | 1 | 0.7 | |||
| Nigeria | 1 | 0.7 | |||
| Pakistan | 1 | 0.7 | |||
| Peru | 3 | 2.1 | |||
| Philippines | 1 | 0.7 | |||
| Portugal | 1 | 0.7 | |||
| Qatar | 1 | 0.7 | |||
| Romania | 1 | 0.7 | |||
| Russia | 2 | 1.4 | |||
| Saudi Arabia | 1 | 0.7 | |||
| Serbia | 2 | 1.4 | |||
| Singapore | 1 | 0.7 | |||
| Republic of Korea | 1 | 0.7 | |||
| Spain | 6 | 4.2 | |||
| Switzerland | 4 | 2.8 | |||
| Taiwan | 2 | 1.4 | |||
| Thailand | 1 | 0.7 | |||
| Turkey | 5 | 3.5 | |||
| United Arab Emirates | 1 | 0.7 | |||
| United Kingdom | 5 | 3.5 | |||
| United States of America | 11 | 7.7 | |||
| Venezuela | 3 | 2.1 | |||
| Overall | 142 | 100 | |||
* numbers are super-additive.